24 companies · FY2026 results (earnings releases, consolidated)
Takeda ranks first for revenue in the Pharmaceutical industry at ¥4.5T. The top three are Takeda (¥4.5T), Suzuken (¥2.5T) and Otsuka (¥2.5T).
Across the 24 companies the average is ¥823.5B and the median ¥317.7B. Peptide Dream comes last at ¥18.5B, a gap of about 243x to the leader.
7 of 24 companies are above the average.
Shares 1Y is a closing-price reference (vs. about a year earlier). YoY compares with the previous full-year results.
| Rank | Company | Revenue | Average salary | Operating profit | Operating margin |
|---|---|---|---|---|---|
| 1 | Takeda4502 | ¥4.5T | ¥11.0M | ¥408.8B | 9.1% |
| 2 | Suzuken9987 | ¥2.5T | ¥7.45M | ¥36.4B | 1.5% |
| 3 | Otsuka4578 | ¥2.5T | ¥10.6M | ¥479.4B | 19.4% |
| 4 | Astellas4503 | ¥2.1T | ¥10.5M | ¥382.6B | 17.9% |
| 5 | Daiichi Sankyo4568 | ¥2.1T | ¥11.0M | ¥229.1B | 10.8% |
| 6 | Chugai4519 | ¥1.3T | ¥12.1M | ¥598.8B | 47.6% |
| 7 | Eisai4523 | ¥825.4B | ¥11.2M | ¥44.1B | 5.3% |
| 8 | Ono4528 | ¥515.8B | ¥10.2M | ¥92.2B | 17.9% |
| 9 | Shionogi4507 | ¥499.7B | ¥10.0M | ¥166.7B | 33.4% |
| 10 | Kyowa Kirin4151 | ¥496.8B | ¥9.94M | - | - |
| 11 | Sumitomo Pharma4506 | ¥453.3B | ¥9.06M | ¥107.3B | 23.7% |
| 12 | Rohto4527 | ¥343.7B | ¥8.26M | ¥41.1B | 12.0% |
| 13 | Santen4536 | ¥291.6B | ¥9.02M | ¥47.8B | 16.4% |
| 14 | Towa4553 | ¥273.7B | ¥6.95M | ¥23.1B | 8.4% |
| 15 | Sawai4887 | ¥201.7B | ¥9.38M | ¥15.9B | 7.9% |
| 16 | Tsumura4540 | ¥192.6B | ¥9.11M | ¥35.2B | 18.3% |
| 17 | Nippon Shinyaku4516 | ¥170.8B | ¥9.19M | ¥35.5B | 20.8% |
| 18 | Kobayashi4967 | ¥165.7B | ¥7.57M | ¥14.9B | 9.0% |
| 19 | Kissei4547 | ¥97.4B | ¥7.98M | ¥-2.9B | -3.0% |
| 20 | Zeria4559 | ¥89.2B | ¥7.99M | ¥12.4B | 13.9% |
| 21 | Kaken4521 | ¥76.9B | ¥8.75M | ¥-899M | -1.2% |
| 22 | JCR4552 | ¥40.3B | ¥8.19M | ¥555M | 1.4% |
| 23 | Nxera4565 | ¥29.6B | ¥12.6M | ¥-8.5B | -28.6% |
| 24 | Peptide Dream4587 | ¥18.5B | ¥11.7M | ¥-5.0B | -27.1% |
Revenue and operating profit are from the latest full-year consolidated results. Average salary is for the reporting entity per its annual securities report; pure holding companies with fewer than 50 staff are excluded.
